MA41411A - Compositions dispersibles - Google Patents

Compositions dispersibles

Info

Publication number
MA41411A
MA41411A MA041411A MA41411A MA41411A MA 41411 A MA41411 A MA 41411A MA 041411 A MA041411 A MA 041411A MA 41411 A MA41411 A MA 41411A MA 41411 A MA41411 A MA 41411A
Authority
MA
Morocco
Prior art keywords
dispersible compositions
dispersible
compositions
Prior art date
Application number
MA041411A
Other languages
English (en)
Other versions
MA41411B1 (fr
Inventor
Manish Kumar Gupta
Shripad Wasudeo Marathe
Shreedevi Velayudhan Nair
Kaustubh Ramesh Tambwekar
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55229712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41411(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA41411A publication Critical patent/MA41411A/fr
Publication of MA41411B1 publication Critical patent/MA41411B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA41411A 2015-01-27 2016-01-26 Compositions dispersibles MA41411B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN264MU2015 2015-01-27
PCT/EP2016/051545 WO2016120258A1 (fr) 2015-01-27 2016-01-26 Compositions dispersibles

Publications (2)

Publication Number Publication Date
MA41411A true MA41411A (fr) 2017-12-05
MA41411B1 MA41411B1 (fr) 2023-07-31

Family

ID=55229712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41411A MA41411B1 (fr) 2015-01-27 2016-01-26 Compositions dispersibles

Country Status (29)

Country Link
US (2) US20180000810A1 (fr)
EP (1) EP3250182B1 (fr)
JP (3) JP7291458B2 (fr)
KR (1) KR102631986B1 (fr)
CN (2) CN107205945A (fr)
AU (2) AU2016212116B2 (fr)
CY (1) CY1126107T1 (fr)
DK (1) DK3250182T3 (fr)
EA (1) EA201791701A1 (fr)
ES (1) ES2948805T3 (fr)
FI (1) FI3250182T3 (fr)
HK (1) HK1243644A1 (fr)
HR (1) HRP20230616T1 (fr)
HU (1) HUE062481T2 (fr)
IL (2) IL310920A (fr)
LT (1) LT3250182T (fr)
MA (1) MA41411B1 (fr)
MD (1) MD3250182T2 (fr)
MX (1) MX391192B (fr)
PE (1) PE20171319A1 (fr)
PH (1) PH12017501331B1 (fr)
PL (1) PL3250182T3 (fr)
PT (1) PT3250182T (fr)
RS (1) RS64308B1 (fr)
SG (1) SG11201705944TA (fr)
SI (1) SI3250182T1 (fr)
SM (1) SMT202300188T1 (fr)
UA (1) UA126891C2 (fr)
WO (1) WO2016120258A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
KR20240108542A (ko) * 2017-07-14 2024-07-09 얀센 파마슈티카 엔브이 장기 작용 제형
US20210100786A1 (en) * 2018-04-05 2021-04-08 Cipla Limited Pharmaceutical Formulations
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
JP7654544B2 (ja) * 2018-12-13 2025-04-01 マンカインド コーポレイション ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
KR20210113628A (ko) * 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
WO2021257466A1 (fr) * 2020-06-15 2021-12-23 The Global Alliance For Tb Drug Development, Inc. Composition antibactérienne combinée et procédé de thérapie antibactérienne
WO2021257461A1 (fr) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
TW202233168A (zh) * 2020-11-12 2022-09-01 比利時商健生藥品公司 治療非結核分枝桿菌疾病的藥物組分之組合
KR102478006B1 (ko) 2020-12-03 2022-12-15 정승찬 자동차 긴급 제동장치
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation
CN120731072A (zh) * 2022-12-17 2025-09-30 维亚治疗有限责任公司 用于治疗儿科结核病的氯法齐明迷你片剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00131B (fr) 2002-07-25 2010-10-10 Janssen Pharmaceutica Nv Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens
CN1976704B (zh) * 2004-05-28 2012-12-05 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
MX2007014874A (es) * 2005-05-25 2008-02-15 Janssen Pharmaceutica Nv Procedimiento para la preparacion del (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil -beta-fenil-3-quinolinaetanol.
CA2528849C (fr) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Derives de quinoleine utilises comme agents antibacteriens
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
WO2009146097A1 (fr) * 2008-04-02 2009-12-03 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques de raloxifène
BRPI0918802A2 (pt) * 2008-09-03 2019-09-17 Pfizer uso de (s)-n-[[3-[3-fluoro-4-(4-tiomorfolinil)fenil]-2-oxo-5-oxazolidinil] metil] acetamida e composição farmacêutica
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
WO2013153162A1 (fr) * 2012-04-11 2013-10-17 Sandoz Ag Polymorphe de chlorhydrate de rilpivirine
US20140075692A1 (en) * 2012-09-18 2014-03-20 Unger Marketing International, Llc. Multiuse cleaning tool handle
EA201590732A1 (ru) * 2012-11-19 2016-01-29 Азанта А/С Диспергируемая таблетка

Also Published As

Publication number Publication date
IL253626B2 (en) 2024-08-01
AU2016212116A1 (en) 2017-07-27
KR102631986B1 (ko) 2024-01-30
PH12017501331A1 (en) 2017-12-11
US20220331307A1 (en) 2022-10-20
PE20171319A1 (es) 2017-09-07
CA2973301A1 (fr) 2016-08-04
CN114129526A (zh) 2022-03-04
HUE062481T2 (hu) 2023-11-28
PH12017501331B1 (en) 2024-02-14
WO2016120258A1 (fr) 2016-08-04
KR20170106447A (ko) 2017-09-20
EP3250182B1 (fr) 2023-04-26
AU2016212116B2 (en) 2021-07-15
CN107205945A (zh) 2017-09-26
MX391192B (es) 2025-03-21
IL253626B1 (en) 2024-04-01
BR112017015784A2 (pt) 2018-03-27
US20180000810A1 (en) 2018-01-04
JP2018502928A (ja) 2018-02-01
JP2022176982A (ja) 2022-11-30
SMT202300188T1 (it) 2023-07-20
ES2948805T3 (es) 2023-09-19
PT3250182T (pt) 2023-07-07
SG11201705944TA (en) 2017-08-30
MA41411B1 (fr) 2023-07-31
AU2021204135B2 (en) 2023-10-05
EP3250182A1 (fr) 2017-12-06
EA201791701A1 (ru) 2017-11-30
JP7291458B2 (ja) 2023-06-15
RS64308B1 (sr) 2023-07-31
CY1126107T1 (el) 2023-11-15
IL310920A (en) 2024-04-01
MD3250182T2 (ro) 2023-09-30
HK1243644A1 (zh) 2018-07-20
PL3250182T3 (pl) 2023-07-31
FI3250182T3 (fi) 2023-06-28
IL253626A0 (en) 2017-09-28
AU2021204135A1 (en) 2021-07-15
JP2021098706A (ja) 2021-07-01
LT3250182T (lt) 2023-07-10
DK3250182T3 (da) 2023-06-26
SI3250182T1 (sl) 2023-08-31
UA126891C2 (uk) 2023-02-22
MX2017009681A (es) 2017-10-18
HRP20230616T1 (hr) 2023-09-29

Similar Documents

Publication Publication Date Title
EP3534968A4 (fr) Compositions de lymphocytes t car anti-bcma
DK3361870T3 (da) Fungicidsammensætninger
PT3355990T (pt) Compostos semifluorados e as suas composições
DK3215173T3 (da) Glycopeptidsammensætninger
MA41411A (fr) Compositions dispersibles
EP3297455A4 (fr) Compositions de glycoside
EP3339331A4 (fr) Composition
EP3398996A4 (fr) Composition
DK3334726T3 (da) Plinabulinsammensætninger
PT3261437T (pt) Compostos e composições fungicidas
EP3388505A4 (fr) Composition de tensio-actif
DK3296597T3 (da) Krydshovedmotor
EP3395887C0 (fr) Composition de caoutchouc fluoré
DK3322295T3 (da) Sammensætning
EP3388504A4 (fr) Composition de tensio-actif
DK3316857T3 (da) Multifasiske sammensætninger
DK3317458T3 (da) Mineralsammensætninger
MA46563A (fr) Compositions dispersibles
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija
EP3369418A4 (fr) Composition
BR112017016240A2 (pt) composição
DK3200827T3 (da) Sammensætninger
DK3337322T3 (da) Fungicidsammensætninger
LT3359185T (lt) Priešnavikinė kompozicija